Endocavitary Ir-192 radiation and laser treatment for palliation of obstructive rectal cancer

Eur J Surg Oncol. 1997 Oct;23(5):428-31. doi: 10.1016/s0748-7983(97)93724-0.

Abstract

Endoscopic laser therapy (ELT) either alone or combined with endocavitary Ir-192 radiation is performed for advanced, inoperable rectal cancer and when patients are ineligible for surgery due to severe concomitant medical illness. During the period from January 1984 to January 1997 we treated 81 patients (51 males, 30 females). Sixty-seven patients had ELT only using a ND-Yag Laser system. Twenty-five patients (average age: 80.5 years) were ineligible for surgery (Group I). Forty-two patients (74.1 years) had an advanced locally inoperable tumour (Group II). Fourteen patients (76.5 years) underwent a combined therapeutic regime with endocavitary Ir-192 afterloading following ELT (Group III). Adequate desobliteration was achieved in 100% (groups I and III) and 97% (group II) of the patients. The average interval to aftertreatment was 8.4 weeks in group I and 9.4 weeks in group II, compared to 11.5 weeks in group III. Serious complications (perianal abscess, rectovaginal fistula) occurred in 3.7%, minor complications (laser-induced bleedings, unclear fever) in 12.3%. All laser-induced bleedings could be dealt with using laser therapy. The frequency of treatment was governed by tumour mass and the patient's survival. The results suggest that additional endocavitary radiation significantly prolongs the maintenance of normal bowel function compared with laser therapy alone.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Brachytherapy*
  • Female
  • Humans
  • Intestinal Obstruction / etiology*
  • Iridium Radioisotopes / therapeutic use*
  • Laser Therapy*
  • Male
  • Palliative Care*
  • Proctoscopy
  • Rectal Neoplasms / complications
  • Rectal Neoplasms / radiotherapy*
  • Treatment Outcome

Substances

  • Iridium Radioisotopes